Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS

Core Viewpoint - The U.S. FDA has extended the review timeline for Travere Therapeutics' supplemental New Drug Application for FILSPARI® in the treatment of focal segmental glomerulosclerosis, with a new target action date set for April 13, 2026 [1] Group 1 - The FDA's extension follows the recent submission of additional responses requested to further characterize the clinical benefit of FILSPARI® [1]